Introduction
HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, accounting for approximately 70% of cases. This subtype, characterized by hormone receptor positivity and the absence of HER2 overexpression, has historically been treated with hormonal therapies and chemotherapy. However, emerging drug therapies are revolutionizing the treatment landscape, offering new...
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian